Scenesse (Afamelanotide Implant 16mg)

SCENESSE (afamelanotide 16mg) is a controlled-release formulation to deliver the photoprotective effects of this melanocortin. Skin pigmentation is activated immediately and the photoprotective effect lasts up to two months.

Recent Rosacea Blog Posts

Melanin also Protects You from Radiation !

Startling news today from the Clinuvel Blog: Melanin also has the ability to protect from radioactive emissions like X-rays and Gamma-rays. How interesting that the chemical that is responsible for skin coloring can also offer protection from high energy particles. These sorts of particles can create free radicals that then lead to all sorts of […]

Continue Reading

For those following the progress of the development of Scenesse (formerly Afamelanotide), some good results from Phase II trials in treating Solar Urticaria. Solar Urticaria is a rare skin condition that can be thought of as being like hives caused my exposure to the sun. Participants received a 16mg implant of Scenesse and were found […]

Continue Reading

Afamelanotide (Scenesse) now available in Italy

Clinuvel has announced today that Italy has pre-empted the approval of Afamelanotide by the FDA in the US by approving it for the treatment of erythropoietic protoporphyria (EPP). Despite the relatively small number of participants in the Italian trial to treat EPP, and the small number of EPP sufferers thought to directly benefit from this […]

Continue Reading



Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.